MedscapeLIVE logo

Getting Into Focus on the Details of Diagnosing and Treating CIDP

A 3 Part Series

5:00 pm – 6:00 pm  TZ

Virtual
CME
swoosh
swoosh

Developed through the strategic collaboration between

 

Webinar 1: An Expert Review of Case Challenges in Diagnosing Chronic Inflammatory Demyelinating Polyneuropathy

Thursday, July 28, 2022, 1:00 - 1:30 PM ET

Chronic inflammatory demyelinating polyneuropathy (CIDP) affects 2 or 3 in 100,000 people and peaks in incidence among those aged 40 to 60 years. CIDP is most likely the result of autoimmune inflammation of peripheral nerves and can present as a monophasic, progressive, or relapsing and remitting disease, causing symmetrical weakness in both proximal and distal muscles. This weakness, along with sensory loss, leads to difficulty walking and hyporeflexia or areflexia. The variability in terms of clinical presentation, pathogenesis, autoantibody profile, disease progression, and response to treatment make CIDP challenging for physicians to diagnose. Delays can lead to axonal loss associated with the progressive demyelination process of the disease. Join Dr Cornblath in this live-streamed video webcast as he discusses the 2021 updates to the CIDP diagnosis and management guidelines with clinical, electrophysiological, immunological, and genetic characteristics of the CIDP variants to help increase diagnostic accuracy for affected patients.

 

Webinar 2: Starting Treatment in Chronic Inflammatory Demyelinating Polyneuropathy: A Review of Clinical Cases

Thursday, August 25, 2022, 12:30 - 1:00 PM ET

Chronic inflammatory demyelinating polyneuropathy (CIDP) affects 2 or 3 in 100,000 people and peaks in incidence in those aged 40 to 60 years. CIDP is most likely the result of autoimmune inflammation of peripheral nerves and can present as a monophasic, progressive, or relapsing and remitting disease, causing symmetrical weakness in both proximal and distal muscles. This weakness, along with sensory loss, leads to difficulty walking and hyporeflexia or areflexia. The variability in terms of clinical presentation, pathogenesis, auto-antibody profile, disease progression, and response to treatment make CIDP challenging for physicians to diagnose and manage. Delays can lead to axonal loss associated with the progressive demyelination process of the disease. Join Dr Beydoun in this live-streamed video webcast as he discusses the goals of treatment and the options for the management of CIDP using illustrative cases.

 

Webinar 3: Case Recommendations in the Modification of Treatment in Chronic Inflammatory Demyelinating Polyneuropathy

Wednesday, September 14, 2022, 11:30 AM - 12:00 PM ET

The European Federation of Neurological Societies (EFNS)/Peripheral Nerve Society (PNS) consensus guideline on the diagnosis and management of chronic inflammatory demyelinating polyradiculoneuropathy was updated in 2021. The goal was to provide evidence-based recommendations for clinical practice to improve patient outcomes. Learn with Dr Karissa Gable, and through some case illustrations, how to assess a treated patient for objective treatment response, when to reconsider the diagnosis and management strategy, and how treatment options can be used to accommodate patients' preferences and optimize long-term response.

 

TARGET AUDIENCE

Target Audience - Dolor sit amet consectetur adipiscing elit ut

GOAL STATEMENT

Goal Statement - Nibh venenatis cras sed felis eget. In cursus turpis massa tincidunt dui ut ornare.

LEARNING OBJECTIVES

Upon completion of this activity, participants will: Have increased knowledge regarding the [list][item]Learning objective one [item]Learning objective two [/list]Have greater competence related to: [list][item]Learning objective one [item]Learning objective two [/list]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.0 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [bold]For Nurses[/bold] Medscape, LLC designates this live activity for a maximum [bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.0 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

⌃